Celltrion (068270) Stock Price, Fundamentals & Analysis

What 068270 does

Celltrion (068270) is a biopharmaceutical company headquartered in Incheon, South Korea, that develops, produces, and sells medicinal products. Its portfolio is focused on biosimilars — medicines that are highly similar to already-approved biological treatments — as well as other specialty biologics. Key products include Remsima for rheumatoid arthritis and inflammatory bowel disease, Truxima for non-Hodgkin's lymphoma and chronic lymphocytic leukemia, Herzuma for metastatic breast and gastric cancer, Vegzelma for metastatic colorectal cancer and non-small cell lung cancer, Omlyclo for asthma and urticaria, Regkirona for COVID-19, and several others covering areas such as osteoporosis, psoriasis, and Alzheimer's dementia symptoms. The company operates in the Healthcare sector, specifically the Biotechnology industry, and trades on the Korea Exchange. It is part of the KOSPI 200, and peers in the Korean biopharma space include Samsung Epis (0126Z0), Green Cross (006280), Hanmi Pharm (128940), Hanmi Science (008930), Chong Kun Dang (185750), SK Bioscience (302440), and Daewoong Pharmaceutical (069620).

Key numbers explained

• 177,400 KRW is the current share price, representing the cost to buy one share of Celltrion on the Korea Exchange.
• The forward P/E ratio (price-to-earnings ratio) of 23.2 is calculated using expected future earnings; it tells investors how much the market is willing to pay per unit of anticipated earnings, with a lower figure often interpreted as relatively cheaper.
• 0.4% is the dividend yield (dividend yield), which shows the annual dividend income as a percentage of the share price; a low yield like this is common for growth-oriented biopharma firms.
• The ex-dividend date of Dec 29, 2025 is the cutoff: you must own the stock before this date to receive the upcoming dividend payment.
• 10% is the share of earnings paid out as dividends, meaning the company returns a modest portion of its profit to shareholders and retains the rest for reinvestment.
• Beta of 0.3 measures the stock's volatility relative to the overall market; a beta below 1 suggests Celltrion's price tends to move less dramatically than the broader market.
• The 52-week range of 158,500 – 239,047.62 KRW shows the lowest and highest prices over the past year, helping investors gauge current price positioning.
• 4.3% is the price change over the last 52 weeks, indicating the total return from one year ago to the current price.
• 4.9T KRW in trailing 12-month revenue and 45% year-over-year revenue growth highlight the scale and recent top-line expansion of the business.
• 32.2% profit margin and 32.4% operating margin indicate that roughly a third of revenue translates into net and operating profit, respectively.
• 9.1% return on equity (ROE) shows how effectively the company generates profit from shareholders' equity.
• 21.4% debt-to-equity ratio reflects a relatively low level of debt compared to equity, which is often viewed as a conservative capital structure.
• 2,956 employees and the Incheon, South Korea headquarters provide context on the company's operational scale and base.
• The next earnings date of Oct 29, 2026 is the scheduled release for the company's upcoming financial results.

What to watch

When following Celltrion (068270), several general factors can influence its stock: biosimilar pipeline progress and regulatory approvals in major markets, pricing pressure from healthcare systems and competition within the biotechnology industry, foreign exchange movements given its Korea Exchange listing, and broader sector trends in healthcare and biopharma R&D spending. Investors also monitor upcoming results tied to the next earnings date of Oct 29, 2026, as well as the ex-dividend date of Dec 29, 2025 for any income-related decisions. The stock's relatively low beta of 0.3 suggests it may be less volatile than the market, but its valuation metrics, such as the forward P/E ratio of 23.2, should be considered alongside industry peers and overall market conditions.